Owned by the Association for International Promotion & Study in Tumors (APSIT)
EMID2 is a novel biotherapeutic for aggressive cancers identified by in vivo screening
New drugs to tackle the next pathway or mutation fueling cancer are constantly proposed, but 97% of them are doomed to fail in clinical trials, largely because they are identified by cellular or in silico scre...